A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis

What Was Tested

The paper reports a study of Leuprolide and Buserelin in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

The study group was 67 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.

In each group the researchers evaluated the symptoms of genital bleeding and hot flashes during GnRHa treatment, as well as the levels of serum LH, FSH, and estradiol 8 weeks after the start of treatment.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In addition, the endometrial thickness was measured by transvaginal ultrasonography, and changes in the volume of the uterine leiomyoma or endometrial cyst at the end of treatment.

The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Buserelin, Endometriosis, Endometrium, Estradiol, Follicle Stimulating Hormone and Gonadotropin-Releasing Hormone.

What This Means in Plain Language

The paper is a randomized study of Leuprolide and Buserelin in 67 patients in people with endometriosis.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (The journal of obstetrics and gynaecology research), a journal based in Australia.

More context: the Leuprolide compound page and the Buserelin compound page, Endometriosis research.